Insights on Health Care
1271 total results. Page 2 of 51.
Massachusetts proposed amendments to the regulations that govern skilled nursing facilities (SNFs). Here is what operators, real property owners, and investors need to know as they acquire facilities, change managers, and navigate licensure renewals in Massachusetts.
The longevity ecosystem sits at the crossroads of health care, life sciences, consumer wellness, artificial intelligence (AI), and other emerging technologies.
In recent months, three federal courts have refused to enforce expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, concluding that the subpoenas were issued for an improper purpose or exceeded the government’s statutory authority.
Headlines that Matter for Companies and Executives in Regulated Industries
Life Sciences Industry Group Co-Leader Stephanie Trunk was quoted on the US Department of Health and Human Services’ Office of Inspector General (OIG) guidance that pharmaceutical manufacturers would face a “low risk” of violating federal anti-kickback laws when selling directly to patients through the planned TrumpRx site.
On January 27, the US Department of Health and Human Services Office of Inspector General (OIG) issued a Special Advisory Bulletin providing significant guidance for pharmaceutical manufacturers offering prescription drugs through direct-to-consumer (DTC) programs to patients enrolled in federal health care programs.
Headlines that Matter for Companies and Executives in Regulated Industries
On behalf of a coalition of the nation’s leading organizations dedicated to the care, health, education, well-being, and welfare of children and families, ArentFox Schiff, filed an amicus brief in the US Court of Appeals for the Ninth Circuit in support of the plaintiffs.
ArentFox Schiff is pleased to announce the launch of its Longevity & Healthspan Industry Group, a cross-sector initiative supporting the rapidly expanding ecosystem of companies advancing anti-aging innovation, wellness, and preventive health.
False Claims Act Investigations Partners Hillary Stemple (Health Care) and Nadia Patel (Litigation) will host a Continuing Education webinar on recent trends in health care fraud enforcement for the Health Care Compliance Association on January 27, 2026.
Headlines that Matter for Companies and Executives in Regulated Industries
Pascal Naples was quoted on a recent “unfavorable” opinion published by the Office of Inspector General (OIG) for the US Department of Health and Human Services that sign-on bonuses for caregivers providing in-home care for Medicaid recipients would fall under the anti-kickback statute.
With 2026 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.
Headlines that Matter for Companies and Executives in Regulated Industries
On January 6, the US Food and Drug Administration (FDA) released two significant updates potentially important for companies operating in the consumer health technology space.
Headlines that Matter for Companies and Executives in Regulated Industries
The enforcement landscape entering 2026 points to sustained False Claims Act activity across traditional health care fraud, AI-enabled misconduct, civil rights–based claims, customs and tariff fraud, and expanding theories of investor liability.
The telehealth industry is entering a new phase of scrutiny marked by intensified enforcement actions across civil and criminal fronts that reflect a coordinated, whole-of-government approach.
Last month, a federal court in Maine halted the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) 340B Rebate Model Pilot Program in its tracks — a mere four days before it was to go into effect.
As we approach the end of the first year of the second Trump Administration, many in the health care sector continue to closely watch federal enforcement trends to identify government priorities going forward.
For the past several years, the use of contract sales forces by pharmaceutical and device manufacturers and other suppliers has been under a heightened enforcement spotlight.
The California Department of Public Health (CDPH) denied two petitions to amend the hospital licensing regulations in Title 22 of the California Code of Regulations to allow advanced practice providers to be members of organized medical staffs in general acute care hospitals.
On December 18, President Trump issued an executive order (EO) directing the Attorney General to complete rulemaking to reschedule “marijuana” from Schedule I to Schedule III under the Controlled Substances Act (CSA) and to expand federal research and policy development on medical marijuana and hemp derived cannabinoids.
The Centers for Medicare & Medicaid Services (CMS) Innovation Center has announced the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model, a 10‑year voluntary payment model that introduces outcome‑aligned payments (OAPs) to expand access to technology‑supported care for Medicare beneficiaries with common chronic conditions.
The past year has been unusually active on the health care antitrust front. Providers are pressing price-fixing and information-exchange theories against payers and claims intermediaries and a landmark class settlement moving into its implementation phase.